Core Insights - Coherus Oncology is set to present CHS-114, an anti-CCR8 cytolytic antibody, at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) from November 5-9, 2025 [1][2] - CHS-114 has shown selective intratumoral Treg depletion and favorable immune remodeling in patients with advanced solid tumors [2] - The company is focused on enhancing its immuno-oncology pipeline, which includes multiple antibody candidates aimed at improving patient outcomes in cancer treatment [4] Company Overview - Coherus Oncology is a fully integrated commercial-stage innovative oncology company with an approved PD-1 inhibitor, LOQTORZI® (toripalimab-tpzi), and a promising proprietary pipeline [3] - The company aims to grow sales of LOQTORZI in nasopharyngeal carcinoma and explore new indications in combination with its pipeline candidates and partners [3] - Coherus' pipeline includes candidates targeting various cancers, including liver, lung, head & neck, colorectal, gastric, and esophageal cancers [4] Upcoming Events - CHS-114 will be featured in a live webinar series titled "Targets for Cancer IO: A Deep Dive" on October 22, 2025, discussing the therapeutic target CCR8 and its implications in cancer treatment [2][8] - The webinar will include discussions on the mechanisms and clinical results of anti-CCR8 antibodies, highlighting the latest advances in this area [2]

Coherus BioSciences FY Conference Summary Company Overview - Coherus BioSciences has transitioned from a biosimilar company to a full immuno-oncology (IO) company, divesting its biosimilar business over the past year and acquiring Surface Oncology in 2023, which added key assets CHS-114 and Casdozokitug to its pipeline [4][6] Core Strategies and Differentiation - The company focuses on combining its PD-1 agent, Toripalimab, with other agents like CHS-114 and Casdozokitug to enhance patient outcomes in various cancers [5][6] - Coherus emphasizes partnerships and collaborations, aiming to validate its platform, generate income, and share costs for pivotal trials [6][7] - The company plans to focus on ex-U.S. partnerships and licensing, with global rights to its assets acquired through recent acquisitions [6][8] Product Performance and Market Position - LOQTORZI, the company's product, has been positioned at the top of NCCN guidelines, leading to a 36% increase in utilization from Q1 to Q2 2025 [12] - The company anticipates reaching $150 to $200 million in revenue by mid-2028, although early adoption may be uneven due to the nature of the patient population [12][13] - 90% of NCCN institutions have ordered LOQTORZI, indicating strong performance in academic centers, while community settings require more educational efforts [14][15] Pipeline Developments - Casdozokitug, an IL-27 antagonist, is in a phase 2 study for first-line HCC, showing promising early responses and safety profiles [16][18] - CHS-114, a CCR8 antibody, is in several phase 1 studies, targeting T-regs in solid tumors, with early data showing immune activation and robust T-reg depletion [22][23] Competitive Landscape and Market Dynamics - The company does not foresee significant impact from the potential loss of exclusivity for Keytruda, as its products are differentiated and will not be directly affected by biosimilars [25][26] - Coherus is positioned to collaborate with other biotechs, especially in underserved tumor types, enhancing its development capabilities [28] Future Milestones - Upcoming milestones include top-line results from the HCC study on Casdozokitug and further progression of CHS-114 in head and neck and gastric cancers [33] - The company expects to pursue transactions to offset development costs and anticipates earnout payments from its partner Accord Healthcare, which has gained significant market share [34]

Company Overview - Coherus Oncology, Inc. is a fully integrated commercial-stage innovative oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI (toripalimab-tpzi) [4] - The company has a growing revenue stream and a promising proprietary pipeline that includes two mid-stage clinical candidates targeting various cancers such as liver, lung, and head & neck [4] Product and Pipeline - LOQTORZI is being positioned to grow sales in nasopharyngeal carcinoma and advance new indications in combination with pipeline candidates and partners [4] - The immuno-oncology pipeline includes multiple antibody immunotherapy candidates aimed at enhancing immune responses for better cancer treatment outcomes [5] - Casdozokitug, a novel IL-27 antagonistic antibody, is currently in multiple Phase 1/2 and Phase 2 studies for advanced solid tumors, including non-small cell lung cancer (NSCLC) and hepatocellular carcinoma (HCC) [5] - CHS-114, a selective cytolytic anti-CCR8 antibody, is in Phase 1b studies for advanced solid tumors, including head and neck squamous cell carcinoma (HNSCC), gastric cancer, and esophageal cancer [5] Upcoming Events - Coherus will be participating in several upcoming conferences, including the Baird 2025 Global Healthcare Conference on September 9, 2025, and the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025 [6] - A virtual event, UBS Virtual Oncology Day, is scheduled for October 1, 2025 [6] - Presentations will be accessible via webcast, with replays available for 30 days [1]

Financial Results Announcement - Coherus Oncology will release its second quarter 2025 financial results after market close on August 7, 2025 [1] - A conference call and webcast will be hosted by Coherus' management team starting at 5:00 p.m. EDT on the same day to discuss the financial results and provide a business update [1][3] Webcast and Access Information - A replay of the webcast will be available on the Coherus investor website following the live conference call [2] - The press release with the financial results and related materials will be accessible on the investor website before the conference call begins [3] Company Overview - Coherus Oncology is a fully integrated commercial-stage innovative oncology company with an approved PD-1 inhibitor, LOQTORZI, and a promising pipeline including two mid-stage clinical candidates targeting various cancers [6] - The company aims to grow sales of LOQTORZI in nasopharyngeal carcinoma and advance new indications in combination with pipeline candidates and partners [6] Pipeline and Research Focus - Coherus' pipeline includes multiple antibody immunotherapy candidates designed to enhance immune responses against tumors [7] - CHS-114, a selective anti-CCR8 antibody, is in Phase 1b studies for advanced solid tumors, while Casdozokitug, an IL-27 antagonistic antibody, is being evaluated in multiple studies for various cancers [7]

Core Viewpoint - Coherus Oncology has rebranded itself to emphasize its commitment to innovative immuno-oncology therapies, focusing on combination therapies to enhance cancer treatment outcomes [1][2]. Company Overview - Coherus Oncology is a commercial-stage innovative oncology company with a focus on proprietary immuno-oncology medicines [1][10]. - The company has an approved next-generation PD-1 inhibitor, LOQTORZI, which is the only FDA-approved treatment for recurrent or metastatic nasopharyngeal carcinoma in combination with chemotherapy [5][10]. Pipeline and Development - Coherus is developing a portfolio of novel combination therapies aimed at overcoming immune resistance to existing treatments [4]. - LOQTORZI serves as the foundation of the company's immuno-oncology franchise, with ongoing development for additional tumor types [5][10]. - CHS-114, a selective cytolytic CCR8 antibody, is in Phase 1b studies in combination with toripalimab for advanced solid tumors [6]. - Casdozokitug, an IL-27 antagonist, is being evaluated in a randomized Phase 2 study for advanced metastatic hepatocellular carcinoma [7]. Scientific Expertise - The company is supported by a world-class team with deep expertise in oncology drug development, including members from prestigious institutions and companies [8]. - The Scientific Advisory Board includes experts in Treg immunology and cytokine biology, providing valuable insights for navigating the oncology landscape [8].

Core Insights - Coherus BioSciences, Inc. will release its first quarter 2025 financial results on May 12, 2025, after market close [1] - A conference call and webcast will be held at 5:00 p.m. EDT on the same day to discuss the financial results and provide a business update [1][3] - The press release and related materials will be available on the company's investor website prior to the conference call [3][4] Company Overview - Coherus is a fully integrated commercial-stage innovative oncology company with an approved PD-1 inhibitor, LOQTORZI® (toripalimab-tpzi), and a growing revenue stream [6] - The company has a promising pipeline that includes two mid-stage clinical candidates targeting various cancers such as liver, lung, and head & neck [6] - Coherus aims to grow sales of LOQTORZI in nasopharyngeal carcinoma and advance new indications in combination with its pipeline candidates and partners [6] Pipeline Details - Coherus' oncology pipeline features multiple antibody immunotherapy candidates designed to enhance immune responses against tumors [7] - CHS-114, a selective anti-CCR8 antibody, is currently in Phase 1 studies for advanced solid tumors, including head and neck squamous cell carcinoma and gastric cancer [7] - Casdozokitug, an IL-27 antagonistic antibody, is being evaluated in multiple Phase 1/2 and Phase 2 studies for advanced solid tumors, including non-small cell lung cancer and hepatocellular carcinoma [7]

Core Insights - Coherus BioSciences, Inc. will be webcasting its participation in several upcoming conferences, providing access to presentations via its Investor Events section on the company website [1][2] - The company is a fully integrated commercial-stage innovative oncology firm with an approved PD-1 inhibitor, LOQTORZI®, and a promising pipeline of mid-stage clinical candidates targeting various cancers [4] - Coherus' immuno-oncology pipeline includes multiple antibody immunotherapy candidates aimed at enhancing immune responses against tumors, with ongoing studies for novel treatments [5] Company Overview - Coherus is focused on growing sales of LOQTORZI in nasopharyngeal carcinoma and advancing new indications in combination with pipeline candidates and partners [4] - The company has a robust immuno-oncology pipeline, including Casdozokitug, an IL-27 antagonistic antibody, and CHS-114, a selective anti-CCR8 antibody, both in various stages of clinical trials [5] Upcoming Events - Coherus will participate in the Citizens Life Science Conference on May 8, 2025, at 9:00 a.m. EDT [6] - The company will also present at the HCW BioConnect @ Nasdaq NYC 2025 on May 20, 2025, at 12:00 p.m. EDT [6] - Additional participation includes the TD Cowen 6th Annual Oncology Innovation Summit on May 27, 2025, and the Jefferies Global Healthcare Conference on June 4, 2025 [6]